The Impact of Inosine Triphosphatase Variants on Hemoglobin Level and Sustained Virologic Response of Chronic Hepatitis C in Korean
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Kim J.S. | - |
dc.contributor.author | Ahn S.-M. | - |
dc.contributor.author | Jung Y.K. | - |
dc.contributor.author | Kwon Y.K.J. | - |
dc.contributor.author | Kim Y.S. | - |
dc.contributor.author | Choi D.J. | - |
dc.contributor.author | Kim J.H. | - |
dc.date.available | 2020-11-02T22:43:31Z | - |
dc.date.issued | 2013 | - |
dc.identifier.issn | 1011-8934 | - |
dc.identifier.issn | 1598-6357 | - |
dc.identifier.uri | https://scholarworks.korea.ac.kr/kumedicine/handle/2020.sw.kumedicine/11352 | - |
dc.description.abstract | Two variants of the inosine triphosphatase (ITPA: rs1127354, rs7270101) gene cause ITPA deficiency and protect against the hemolytic toxicity of ribavirin. We investigated the clinical significance of ITPA variants in Korean patients treated with pegylated interferon (PEG-IFN) plus ribavirin. Of the 133 patients, 108 were CC and 25 were non-CC at rs1127354 (groups A and B, respectively). On the other hand, at rs7270101 all 133 were AA. The mean values of Hemoglobin (Hgb) after 4, 8, and 12 weeks of treatment in groups A and B were 12.2 and 14.0, 11.8 and 13.2, and 11.5 and 12.9, respectively (P = 0.001, 0.036, 0.036). Sustained virologic response (SVR) was achieved in 67.8% (40/59) of genotype 1 patients and in 75% (27/36) of non-genotype 1 patients. Regarding ITPA variants, SVR was achieved by 66% and 80% of genotype 1 (P = 0.282), and by 78% and 71% (P = 0.726) of non-genotype 1. SVR was not significantly different in groups A and B. In conclusion, non-CC at rs1127354 without involvement of rs7270101 is strongly associated with protection from ribavirin-induced anemia, however, ITPA genotype is not associated with SVR. © 2013 The Korean Academy of Medical Sciences. | - |
dc.format.extent | 7 | - |
dc.language | 영어 | - |
dc.language.iso | ENG | - |
dc.title | The Impact of Inosine Triphosphatase Variants on Hemoglobin Level and Sustained Virologic Response of Chronic Hepatitis C in Korean | - |
dc.type | Article | - |
dc.publisher.location | 대한민국 | - |
dc.identifier.doi | 10.3346/jkms.2013.28.8.1213 | - |
dc.identifier.scopusid | 2-s2.0-84884364955 | - |
dc.identifier.bibliographicCitation | Journal of Korean Medical Science, v.28, no.8, pp 1213 - 1219 | - |
dc.citation.title | Journal of Korean Medical Science | - |
dc.citation.volume | 28 | - |
dc.citation.number | 8 | - |
dc.citation.startPage | 1213 | - |
dc.citation.endPage | 1219 | - |
dc.type.docType | Article | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | sci | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.description.journalRegisteredClass | kci | - |
dc.subject.keywordPlus | alpha interferon | - |
dc.subject.keywordPlus | antivirus agent | - |
dc.subject.keywordPlus | hemoglobin | - |
dc.subject.keywordPlus | IL28B protein, human | - |
dc.subject.keywordPlus | inorganic pyrophosphatase | - |
dc.subject.keywordPlus | inosine triphosphatase | - |
dc.subject.keywordPlus | interleukin derivative | - |
dc.subject.keywordPlus | macrogol derivative | - |
dc.subject.keywordPlus | peginterferon alpha2a | - |
dc.subject.keywordPlus | recombinant protein | - |
dc.subject.keywordPlus | ribavirin | - |
dc.subject.keywordPlus | adult | - |
dc.subject.keywordPlus | allele | - |
dc.subject.keywordPlus | anemia | - |
dc.subject.keywordPlus | article | - |
dc.subject.keywordPlus | Asian | - |
dc.subject.keywordPlus | cohort analysis | - |
dc.subject.keywordPlus | drug combination | - |
dc.subject.keywordPlus | female | - |
dc.subject.keywordPlus | genetics | - |
dc.subject.keywordPlus | genotype | - |
dc.subject.keywordPlus | hemolysis | - |
dc.subject.keywordPlus | hepatitis C | - |
dc.subject.keywordPlus | Hepatitis C virus | - |
dc.subject.keywordPlus | human | - |
dc.subject.keywordPlus | IL28B | - |
dc.subject.keywordPlus | ITPA | - |
dc.subject.keywordPlus | male | - |
dc.subject.keywordPlus | middle aged | - |
dc.subject.keywordPlus | retrospective study | - |
dc.subject.keywordPlus | South Korea | - |
dc.subject.keywordPlus | treatment outcome | - |
dc.subject.keywordPlus | Anemia | - |
dc.subject.keywordPlus | Hepatitis C, Chronic | - |
dc.subject.keywordPlus | IL28B | - |
dc.subject.keywordPlus | ITPA | - |
dc.subject.keywordPlus | Ribavirin | - |
dc.subject.keywordPlus | Adult | - |
dc.subject.keywordPlus | Alleles | - |
dc.subject.keywordPlus | Antiviral Agents | - |
dc.subject.keywordPlus | Asian Continental Ancestry Group | - |
dc.subject.keywordPlus | Cohort Studies | - |
dc.subject.keywordPlus | Drug Therapy, Combination | - |
dc.subject.keywordPlus | Female | - |
dc.subject.keywordPlus | Genotype | - |
dc.subject.keywordPlus | Hemoglobins | - |
dc.subject.keywordPlus | Hemolysis | - |
dc.subject.keywordPlus | Hepacivirus | - |
dc.subject.keywordPlus | Hepatitis C, Chronic | - |
dc.subject.keywordPlus | Humans | - |
dc.subject.keywordPlus | Interferon-alpha | - |
dc.subject.keywordPlus | Interleukins | - |
dc.subject.keywordPlus | Male | - |
dc.subject.keywordPlus | Middle Aged | - |
dc.subject.keywordPlus | Polyethylene Glycols | - |
dc.subject.keywordPlus | Pyrophosphatases | - |
dc.subject.keywordPlus | Recombinant Proteins | - |
dc.subject.keywordPlus | Republic of Korea | - |
dc.subject.keywordPlus | Retrospective Studies | - |
dc.subject.keywordPlus | Ribavirin | - |
dc.subject.keywordPlus | Treatment Outcome | - |
dc.subject.keywordAuthor | Anemia | - |
dc.subject.keywordAuthor | Chronic | - |
dc.subject.keywordAuthor | Hepatitis C | - |
dc.subject.keywordAuthor | Il28b | - |
dc.subject.keywordAuthor | Itpa | - |
dc.subject.keywordAuthor | Ribavirin | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
73, Goryeodae-ro, Seongbuk-gu, Seoul, Republic of Korea (02841)82-2-2286-1265
COPYRIGHT 2020 KOREA UNIVERSITY MEDICAL LIBRARY ALL RIGHTS RESERVED.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.